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Abstract
In 1999, the National Cancer Institute issued a clinical advisory strongly touting the advan-
tage of cisplatin-based chemoradiation (CCRT) for cervical cancer patients requiring radia-
tion for their treatment. This study aimed to compare survival outcomes of cervical
squamous cell carcinoma and adenocarcinoma before and after the advent of CCRT. Data
were obtained from the Korea National Cancer Incidence Database for patients who were
diagnosed with cervical cancers between 1993 and 2012. We compared survival according
to histologic subtypes in cervical cancer patients diagnosed before (1993–1997), during
(1998–2002), and after (2003–2012) the introduction of CCRT. A total of 80,766 patients
were identified, including 64,531 (79.9%) women with squamous cell carcinomas and 7,265
(9.0%) with adenocarcinoma. With the introduction of CCRT, survival trends gradually
increased in patients of both histologic subtypes with regional tumors. However, survival
was significantly higher in squamous cell carcinoma than in adenocarcinoma patients
regardless of treatment modalities (surgery alone, P < 0.001; surgery followed by CCRT,
P < 0.001; or primary CCRT, P = 0.003). Multivariate analysis showed that adenocarcinoma
was an independent negative prognostic factor for survival regardless of the time period
(before CCRT, hazard ratio (HR) = 1.49; 95% confidence interval (CI), 1.37–1.62; after intro-
duction of CCRT, HR = 1.40; 95% CI, 1.30–1.50). Although the survival of adenocarcinoma
has improved after the introduction of CCRT, adenocarcinoma is still associated with worse
overall survival compared to squamous cell carcinoma in the era of CCRT.
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Introduction
Although the incidence and mortality rate for cervical cancer has been decreasing in recent
years, it continues to be a major public health problem worldwide including in East Asia [1–3].
In contrast to a marked decrease in the incidence of squamous cell carcinoma of the cervix,
that of adenocarcinoma has been stable or even increasing [4, 5]. As the current guidelines for
cervical cancer recommend the same treatment regardless of histologic subtypes, increasing
efforts have focused on comparing the prognoses of adenocarcinoma to squamous cell
carcinoma.
Previous studies have evaluated the prognostic role of tumor histology on cervical cancer
outcomes with conflicting results [6–9]. Many of these studies included cohorts that were small
and from single institutions, or included patients treated over long periods of time. Using a
large database, Galic et al. concluded that adenocarcinoma negatively impacts survival outcome
regardless of whether histology shows early or advanced stage disease [6].
In 1999, the National Cancer Institute issued an advisory urging clinicians to strongly con-
sider the use of cisplatin-based concurrent chemoradiation (CCRT) to treat cervical cancer
patients for whom radiation treatment was indicated [10]. Since then, CCRT has been widely
used as a primary or adjuvant treatment option instead of radiation therapy alone in developed
countries [11]. Because of the survival benefits of CCRT, it is prudent to compare its efficacy in
individual histologic subtypes of cervical cancer. Therefore, the aim of this study was to com-
pare the historical changes in survival trends of squamous cell carcinoma versus adenocarci-
noma patients before, during, and after the introduction of CCRT using data from the
Nationwide Cancer Registry. Additionally, we compared overall survival outcomes between
the two histologic subtypes in recent years since the dissemination of CCRT.
Patients and Methods
We analyzed the cervical cancer data from the Korea Central Cancer Registry (KCCR). The
ministry of Health and Welfare initially launched the KCCR as a nationwide, hospital-based
cancer registry in 1980. The KCCR covers the entire population under the Population-Based
Regional Cancer Registry program since 1999 [12]. Furthermore, the Gynecologic Oncology
Committee of the Korean Society of Obstetrics and Gynecology has operated a gynecologic
cancer registry since 1991 [4]. Using these two databases, we could estimate the national cervi-
cal cancer incidences since 1993. We included 72,240 cases from our previous study published
in 2013 [13].
Demographic data collected included age at diagnosis (<40, 40–49, 50–59, and60 years).
Patients were classified based on their tumor histology into the following groups: squamous,
adenocarcinoma, and adenosquamous carcinoma. Staging information was based on the Sur-
veillance, Epidemiology, and End Results (SEER), summary staging (localized, regional, dis-
tant), and Féderation Internationale de Gynécologie et d’Obstétrique (FIGO). Summary
staging is a basic method of categorizing how far a cancer has spread from its origin [14]. Sev-
eral cancer registries in North America report their data by the summary stage, as the staging
categories are broad enough to measure the success of cancer control and other epidemiologic
efforts [15]. For consistency, the FIGO stage was converted to the SEER stage. The year of diag-
nosis was categorized into one of the following ranges: 1993–1997 (before CCRT), 1998–2002
(during CCRT rollout), 2003–2007, and 2008–2012 (both after CCRT).
The National Cancer Center Institutional Review Board approved this study (NCC2015-
0135). The data were obtained and analyzed after anonymized and de-identified.
Age-standardized rates (ASRs) were calculated using the world standard population [16].
Survival analysis was according to 5-year relative survival rates. The relative survival is an
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estimate based on the ratio between the overall survival in a group of patients and overall sur-
vival in a similarly sized group from the general population with same age distribution and
without disease [17]; the details of this method were described previously [18]. We compared
the survival according to histologic subtypes in cervical cancer patients diagnosed before, dur-
ing, and after introduction of CCRT. In Korea, CCRT was adopted as routine practice between
1998 and 2002, and has been commonly performed since 2003 (S1 Table). Categorical variables
were compared with the Pearson chi-square test. The Cox proportional hazards model was
used to evaluate independent prognostic factors and to estimate their covariate-adjusted effects
on relative survival. This model assumes that additive changes in the value of a survival variable
cause corresponding multiplicative changes in the hazard function. All analyses were per-
formed with SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Table 1 shows the demographic characteristics of the study population. A total of 80,766
patients were identified, including 64,531 (79.9%) women with squamous cell carcinomas,
7,265 (9.0%) with adenocarcinoma, and 1,853 (2.3%) with adenosquamous carcinomas. Pri-
mary treatment consisted of surgery in 33,012 (40.9%) patients, followed by primary concur-
rent chemoradiation in 7,216 (8.9%) of the patients encompassing all histologic subtypes.
Table 1. Patient characteristics.
No. of cases %
Age (years)
<40 16,913 20.9
40–49 22,207 27.5
50–59 17,803 22.0
60 23,843 29.5
Stage
Localized 33,609 41.6
Regional 17,757 22.0
Distant 2,786 3.5
Unspeciﬁed 26,614 33.0
Year of Diagnosis
1993–1997 21,688 26.9
1998–2002 21,759 26.9
2003–2007 19,222 23.8
2008–2012 18,097 22.4
Primary treatment
Surgery 33,012 40.9
Chemotherapy 6,933 8.6
Radiation 6,395 7.9
Chemoradiation 7,216 8.9
Surgery + adjuvant chemoradiation 4,647 5.8
Others 22,563 27.9
Histology
Squamous cell carcinoma 64,531 79.9
Adenocarcinoma 7,265 9.0
Adenosquamous carcinoma 1,853 2.3
Unspeciﬁed 7,117 8.8
doi:10.1371/journal.pone.0144887.t001
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While the overall incidence rate of adenocarcinoma remained relatively constant from 1993
to 2012, that of squamous cell carcinoma declined during the same period of time (Fig 1). The
age-standardized incidence rates of adenocarcinoma were in the range of 1.2–1.3 per 100,000,
while those of squamous cell carcinoma declined from 14.1 to 7.0 per 100,000 during the study
period.
Table 2 shows the 5-year relative survival rate (RSR) of patients with cervical cancer accord-
ing to histologic subtypes and SEER stage. During this period, the overall 5-year RSR was not
significantly changed for either squamous cell carcinoma or adenocarcinoma. However, differ-
ences in survival were observed when comparing specific time periods. There was a decrease
(3%) in the 5-year RSR of localized squamous cell carcinoma patients diagnosed in 2008–2012
Fig 1. Cervical cancer incidence trends by tumor histology.
doi:10.1371/journal.pone.0144887.g001
Table 2. Five-year relative survival rate classified by tumor histology.
Year of Diagnosis Difference* P value
1993–1997 1998–2002 2003–2007 2008–2012
Squamous cell carcinoma 81 82.7 83 82 1 0.754
Localized 95.2 95.7 93.4 92.2 -3 < .001
Regional 64.5 69.9 72.4 75.1 10.6 < .001
Distant 21.8 25 30 28.8 7 0.055
Adenocarcinoma 73 79 79.1 78.2 5.2 0.073
localized 89.8 92 90.9 91.3 1.5 0.911
regional 53.7 56.6 65.5 62.8 9.1 0.027
distant 0 24.1 27.3 24.2 24.2 0.863
*percent change in the 5-year relative survival rate of patients diagnosed in 2008–2012 compared to those diagnosed in 1993–1997
doi:10.1371/journal.pone.0144887.t002
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compared to that of those diagnosed in 1993–1997. From 1993 to 2012, survival gradually
increased for patients with regional tumors; the 5-year RSR improved from 64.5% (1993–1997)
to 75.1% (2008–2012) for regional squamous cell carcinoma, corresponding to an increase of
10.6% from 1993 to 2012 (P< 0.001). Furthermore, there was a significant increase in the
5-year RSR for regional adenocarcinoma, corresponding to 9.1% between 1993 and 2012
(P = 0.027).
Relative survival was significantly higher in squamous cell carcinoma than in adenocarci-
noma regardless of treatment modalities (Fig 2). When treated with surgery alone, patients
with adenocarcinoma (n = 1,905) showed a poorer survival outcome compared to those with
squamous cell carcinoma (n = 12,965) (P< 0.001). When treated with surgery followed by
adjuvant CCRT, patients with adenocarcinoma (n = 474) showed a significantly poorer sur-
vival compared to those with squamous cell carcinoma (n = 2,682) (P< 0.001). Moreover,
CCRT-treated patients with adenocarcinoma (n = 302) had poorer survival compared to those
with squamous cell carcinoma (n = 4,245) (P = 0.003).
Cox multivariate modeling was used to analyze prognostic factors for overall-survival in all
patients, controlling for other variables (Table 3). Adenocarcinoma was an independent
Fig 2. Survival curves for patients according to primary treatment classified by tumor histology after (2003–2012) the introduction of
chemoradiation. (A) Surgery alone, (B) Surgery followed by adjuvant chemoradiation, (C) Primary chemoradiation.
doi:10.1371/journal.pone.0144887.g002
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negative prognostic factor for survival regardless of the time period. Before the CCRT era
(1993–1997), patients with adenocarcinoma were 49% more likely to die than those with squa-
mous cell carcinoma (hazard ratio [HR] = 1.49; 95% confidence interval [CI], 1.37–1.62). After
the introduction of CCRT, histology continued to be a factor determining survival. Patients
with adenocarcinoma were 40% more likely to die than those with squamous cell carcinoma
(HR = 1.40; 95% CI, 1.30–1.50).
Discussion
This large population-based epidemiologic study showed that survival improved in regional
tumors after the introduction of CCRT. However, adenocarcinoma was still an independent
negative prognostic factor despite the availability of CCRT. Adenocarcinoma had poorer sur-
vival than squamous cell carcinoma both before and after the introduction of CCRT, suggest-
ing that histologic subtypes have an important impact on survival for women with cervical
cancer.
In this study of 80,766 cases of cervical cancer in Korea, there was an increase in adenocarci-
noma incidence cases from 6.7% in 1993–1997 to 11.2% in 2008–2012. Recent reports show
that the relative and absolute incidences of adenocarcinoma have risen, and now account for
Table 3. Estimated hazard ratio of cervical cancer before, during, and after the introduction of CCRT.
Total 1993–1997 1998–2002 2003–2012
N Adj HR N Adj HR N Adj HR N Adj HR
Age (years)
<40 16,913 0.84 (0.80–0.88) 5,122 0.76 (0.70–0.83) 4,665 0.85 (0.77–0.93) 7,126 0.94 (0.86–1.03)
40–49 22,207 ref 5,652 ref 6,205 ref 10,350 ref
50–59 17,803 1.35 (1.29–1.40) 5,468 1.48 (1.38–1.59) 4,572 1.42 (1.31–1.53) 7,763 1.14 (1.06–1.23)
60 23,843 2.74 (2.64–2.84) 5,446 2.78 (2.61–2.97) 6,317 2.99 (2.79–3.21) 2,080 2.48 (2.33–2.64)
Stage
Localized 33,609 ref 6,322 ref 7,797 ref 19,490 ref
Regional 17,757 2.13 (2.04–2.21) 4,105 2.29 (2.13–2.47) 4,500 2.18 (2.01–2.36) 9,152 1.96 (1.85–2.09)
Distant 2,786 6.73 (6.36–7.12) 268 6.51 (5.65–7.51) 417 6.98 (6.15–7.92) 2,101 6.59 (6.13–7.09)
Year of Diagnosis
1993–1997 21,688 1.05 (1.02–1.09) 21,688 - - - - -
1998–2002 21,759 ref - - 21,759 - - -
2003–2007 19,222 1.03 (0.99–1.07) - - - - 19,222 ref
2008–2012 18,097 0.99 (0.95–1.04) - - - - 18,097 1.00 (0.96–1.05)
Primary treatment
Surgery 33,012 ref 8,032 ref 8,600 ref 16,380 ref
Chemotherapy 6,933 3.74 (3.55–3.94) 3,044 3.27 (3.02–3.54) 2,110 3.41 (3.10–3.76) 1,779 4.77 (4.31–5.29)
Radiation 6,395 4.07 (3.87–4.28) 2,584 3.63 (3.36–3.93) 1,975 3.60 (3.28–3.95) 1,836 5.15 (4.69–5.68)
Chemoradiation 7,216 3.58 (3.39–3.78) 779 4.27 (3.83–4.75) 1,490 3.55 (3.20–3.93) 4,947 4.07 (3.73–4.43)
Surgery + adjuvant chemoradiation 4,647 3.44 (3.22–3.68) 309 4.33 (3.69–5.08) 748 4.05 (3.56–4.60) 3,590 3.73 (3.39–4.11)
Others 22,563 3.67 (3.51–3.83) 6,940 2.96 (2.76–3.18) 6,836 3.29 (3.05–3.56) 8,787 5.02 (4.65–5.42)
Histology
Squamous cell carcinoma 64,531 ref 17,623 ref 17,663 ref 29,245 ref
Adenocarcinoma 7,265 1.44 (1.37–1.51) 1,454 1.49 (1.37–1.62) 1,866 1.45 (1.33–1.58) 3,945 1.40 (1.30–1.50)
Adenosquamous carcinoma 1,853 1.26 (1.15–1.37) 438 1.20 (1.03–1.40) 488 1.39 (1.18–1.63) 927 1.23 (1.01–1.41)
HR, hazard ratio; ref, reference
doi:10.1371/journal.pone.0144887.t003
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approximately 20% of invasive cervical cancer [5, 19]. This may be due to less success in the
diagnosis and treatment of pre-invasive adenocarcinoma compared to squamous cell carci-
noma [20–23]. Given the relative rise in the incidence of adenocarcinoma, its prognostic signif-
icance is of particular importance.
It remains controversial in the field whether the histologic subtype is an independent prog-
nostic factor for cervical cancer. For conclusive study, an appropriate number of adenocarci-
noma cases should be analyzed while controlling for stage and primary treatment. As
sensitivity to radiotherapy has been proposed to vary according to histology [24], our analysis
specifically explored the influence of histologic subtypes, stratified by primary treatment and
time period, on outcome.
Rose et al. compared squamous cell carcinoma, adenocarcinoma, and adenosquamous cell
carcinoma outcomes according to treatment modality [8]. They showed that adenocarcinoma/
adenosquamous carcinoma (n = 182) are associated with worse outcome when treated with
radiation alone, but outcome was similar to squamous cell carcinoma when treated with
CCRT. In contrast, we separated adenocarcinoma and adenosquamous carcinoma and showed
that adenocarcinoma persists as a negative independent prognostic factor even after introduc-
tion of CCRT. Galic et al. performed a sensitivity analysis before (1988–1999) and after (2000–
2005) the introduction of chemoradiation [6]. They showed that adenocarcinoma patients had
significantly lower survival even after adjustment for other demographic and treatment charac-
teristics. We confirmed that adenocarcinoma had worse overall survival than squamous cell
carcinoma regardless of the treatment modality and time period.
This large population-based analysis may reflect the clinical scenarios in other developed
countries where CCRT has become widely available. For regional tumors, primary or adjuvant
CCRT are commonly indicated, and survival benefits have been shown in both histologic sub-
types. However, patients with adenocarcinoma are still 40% more likely to die than those with
squamous cell carcinoma. Hence, adenocarcinoma is probably a distinct clinical entity from
squamous cell carcinoma and is fundamentally different at the molecular level.
Some investigators have suggested that the molecular mechanisms for the pathogenesis of
adenocarcinoma and squamous cell carcinoma are distinct. Significant differences in gene
expression were observed between the two histologic subtypes [25]. Different patterns of P53
mutations were found in squamous cell carcinoma and adenocarcinoma, and the highest fre-
quency of mutated P53 has been observed in Asian adenocarcinoma patients [26]. Moreover,
differential methylation patterns between histologic subtypes were identified; hypermethyla-
tion in PAK6 and NOGOR is strongly correlated with adenocarcinoma [27]. A high-through-
put genotyping platform showed that squamous cell carcinoma and adenocarcinoma have
distinct molecular profiles; KRASmutations were identified only in adenocarcinoma and
EGFRmutation was detected only in squamous cell carcinoma [28].
A decrease in the 5-year RSR for localized squamous cell carcinoma may be explained by
the increased rates of carcinoma in situ. Increasing incidences of squamous cell carcinoma in
situ, coupled with a decreasing trend in invasive squamous cell carcinoma occurrences, were
documented in Korea between 1993 and 2009 [13]. This attests to the success of cervical
screening and treatment of pre-invasive squamous cell carcinoma in the country. Earlier detec-
tion and treatment of carcinoma in situ may result in a decrease of microinvasive cervical can-
cers that progress to a localized stage, which would lead to very favorable outcomes.
This study has limitations. First, central pathology reviews were not performed for patients
registered in the KCCR. Values for histologic subtypes are missing in 8.8% of the study popula-
tion, and the possibility exists that some patients were misclassified. Second, the KCCR lacks
data on some important demographic variables such as FIGO staging and socioeconomic sta-
tus. Lastly, the KCCR lacks data on timing and distribution of recurrences.
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Conclusions
This study demonstrated that patients with adenocarcinoma have worse survival outcomes
than those with squamous cell carcinoma. Considering that current management for adenocar-
cinoma is virtually the same as that for squamous cell carcinoma, prospective studies are war-
ranted to evaluate histology-specific treatment protocols.
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